FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Chris Weber

Senior Director, Global Science Initiatives Alzheimer's Association

Thursday 5th February 2026

Panel Discussion: Patient Perspectives in Neurodegeneration: Shaping the Future of Alzheimer’s & Parkinson’s Drug Development

9:00 am

Hear directly from individuals living with Alzheimer’s and Parkinson’s alongside leading foundations, offering a unified view of lived experience and scientific context
Explore real-world treatment challenges, clinical trial barriers, and the outcomes that matter most to patients across both diseases
Gain actionable, patient-driven insights to inform more inclusive, meaningful, and effective drug development and trial design